Morningstar

PanGIA Biotech Announces Peer-Reviewed Study in Diagnostics Showing 97.8% Sensitivity in Detecting Prostate Cancer Using a Urine-Based Liquid Biopsy with Machine Learning

DELRAY BEACH, Fla., April 2, 2026 /PRNewswire/ -- PanGIA Biotech, Inc. ("PanGIA") announced a peer-reviewed clinical study published in Diagnostics, "Urine-Based Machine Learning Assay Detects ...
Hospital Healthcare Europe

Oliver Hulson on AI-supported prostate cancer diagnoses: quick-fire interview

Dr Oliver Hulson discusses an advanced AI software system being piloted in Leeds to help improve prostate cancer diagnosis ...

How Nanoparticles and AI Can Potentially Help Detect Prostate Cancer and More

An exploration of how targeted nanoparticles and artificial intelligence algorithms combine to locate prostate cancer earlier ...
ascopubs.org

Early prediction of PSA nadir in metastatic castration-sensitive prostate cancer with machine learning approaches.

Predictive value of a pathomics signature in de novo metastatic prostate cancer: An ancillary study of the PEACE-1 phase 3 trial. This is an ASCO Meeting Abstract from the 2026 ASCO Genitourinary ...
Business Insider

Profound Medical Congratulates Texas Prostate on Achieving 100th TULSA Procedure™ Milestone

TORONTO, March 27, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets AI-powered, ...